A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of ERN/LRPT in Patients With Dyslipidemia [Estudio internacional, multicéntrico, doble ciego, aleatorizado, de grupos paralelos y controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad a largo plazo de la niacina de liberación prolongada (ER) y el laropiprant (ERN/LRPT) en pacientes con dislipidemia]

Trial Profile

A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of ERN/LRPT in Patients With Dyslipidemia [Estudio internacional, multicéntrico, doble ciego, aleatorizado, de grupos paralelos y controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad a largo plazo de la niacina de liberación prolongada (ER) y el laropiprant (ERN/LRPT) en pacientes con dislipidemia]

Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2014

At a glance

  • Drugs Niacin/laropiprant (Primary) ; Niacin
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 16 Feb 2012 Actual patient number changed from 1153 to 1152 as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Primary endpoint 'Assessment-scale-scores' has been met, according to results presented at the 84th Annual Scientific Sessions of the American Heart Association.
    • 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top